Neurovascular medtech startup
Location: Ireland, Galway
Employees: 11-50
Total raised: $53.09M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Earlybird ... | earlybird.... |
| 12.02.2022 | Seroba Lif... | seroba-lif... |
| 11.02.2022 | Life Scien... | lspvc.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.03.2025 | - | $23.91M | - |
| 09.02.2022 | Series A | $25.74M | - |
| 29.01.2019 | Seed | $3.43M | Earlybird ... |
Mentions in press and media 18
| Date | Title | Description |
| 26.05.2025 | Let'sGetChecked and Tines deals double VC funding in Q1 | Venture capital funding into Irish SMEs doubled to €533m in the first quarter, powered by nine-figure investments in unicorns LetsGetChecked (€150m) and Tines (€115m). Figures from the Irish Venture Capital & Private Equity Association ... |
| 15.03.2025 | Perfuze: €22 Million Raised And Clearance Received For Zipline Access Catheters | Perfuze, a leading medical device company dedicated to advancing stroke treatment, has received FDA 510(k) clearance for its Zipline Access Catheters. This milestone strengthens Perfuze’s growing portfolio of innovative neurovascular device... |
| 13.03.2025 | Perfuze Raises €22M in Additional Funding | Perfuze, a Galway, Ireland-based medical device company, raised €22M in additional funding. The round was led by existing investors including Earlybird, EQT Life Sciences, Seroba and SV Health. Led by CEO Wayne Allen, Perfuze is a medical d... |
| 20.12.2023 | Perfuze® Announces FDA Clearances for Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment | Galway, Ireland, December 20, 2023 –Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, proudly announces FDA clearance for the Millipede 070 Aspiration Catheter and the 2n... |
| 10.11.2023 | Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System. | Galway, Ireland. 2 November 2023. Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Re... |
| 02.11.2023 | Perfuze Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System | Galway, Ireland, November 2, 2023 –Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for R... |
| 17.07.2023 | Earlybird Health's Inaugural Impact & ESG report reveals opportunities and gaps in investor and startups' commitments | Whether you like it or not, you'll be hearing a lot about ESG (Environmental Social Governance) metrics, commitments, and actions from now to forever. Earlybird is one of Europe's most established and active Venture capital firms published ... |
| 09.06.2023 | Perfuze Announces Appointment of New Chair of the Board. | Galway, Ireland. 9 June, 2023. Seroba portfolio company, Perfuze, a medical device company developing next-generation ”super-bore” catheter technology to treat acute ischemic stroke, is pleased to announce the appointment of Hooman Hakami a... |
| 16.02.2023 | Perfuze Announces FDA Clearance and First U.S. Clinical Use of Millipede 088 Access Catheter. | Galway, Ireland. 16 February 2023. Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration (FD... |
| 16.02.2023 | Perfuze Announces FDA Clearance and First U.S. Clinical Use of Millipede 088 Access Catheter | GALWAY, Ireland--(BUSINESS WIRE)--Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration (FDA... |
Show more